Metronomic chemotherapy: changing the paradigm that more is better

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Scharovsky, O. Graciela
dc.contributor.author Mainetti, Leandro Ernesto
dc.contributor.author Rozados, Viviana R.
dc.date.accessioned 2012-08-24T17:19:08Z
dc.date.available 2012-08-24T17:19:08Z
dc.date.issued 2009-03
dc.identifier.citation Scharovsky, O. G., Mainetti, L. E., & Rozados, V. R. (2009). Metronomic chemotherapy: Changing the paradigm that more is better. Current Oncology, 16, 2, 7-15. es
dc.identifier.issn 1198-0052
dc.identifier.uri http://hdl.handle.net/2133/2008
dc.description.abstract The introduction of the “maximum tolerated dose” in usual treatment protocols (and its concomitant overt toxicity) made necessary the imposition of rest periods between cycles of therapy—a practice that not only involves re-growth of tumour cells, but also growth of selected clones resistant to the therapy. To avoid the problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has been proposed. This name makes reference to the chronic, equally spaced administration of (generally) low doses of various chemotherapeutic drugs without extended rest periods. The novelty of this treatment modality lies not only in its antitumour efficacy with very low toxicity, but also in a cell target switch, now aiming at tumour endothelial cells. The knowledge acquired in the experimental field of metronomic chemotherapy, plus the increasing experience that is being obtained in the clinical setting, will help to lead a change in the design of therapeutic protocols against cancer. es
dc.format application/pdf
dc.language.iso en es
dc.publisher Multimed Inc. es
dc.rights openAccess
dc.subject Metronomic chemotherapy es
dc.subject Angiogenesis es
dc.subject Optimal biologic dose es
dc.subject OBD es
dc.subject Circulating endothelial cells es
dc.subject CECs es
dc.subject Circulating endothelial progenitors es
dc.subject CEPs es
dc.title Metronomic chemotherapy: changing the paradigm that more is better es
dc.type article
dc.type artículo
dc.type publishedVersion
dc.description.peerreviewed Peer reviewed es
dc.relation.publisherversion http://www.current-oncology.com/index.php/oncology/article/view/420/328 es
dc.rights.text © Multimed Inc. es


Files in this item

This item appears in the following Collection(s)

Show simple item record

My Account


Search DSpace


Browse

Statistics